Compared with the general population, older adults with immune senescence and
individuals who are immunocompromised (IC) due to disease or immunosuppressive …

Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a
pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to …

The safety and efficacy of the severe acute respiratory syndrome coronavirus-2 (SARS-
CoV2) emergency-use authorized (EUA) vaccines have been confirmed in the general …

Preventing viral infections at an early stage is a key strategy for successfully improving
transplant outcomes. Preemptive therapy and prophylaxis with antiviral agents have been …

The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes
zoster (HZ) in 2017. We conducted a literature search (January 1, 2017–August 1, 2023) …

Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant
(auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth …

ASCO Guidelines provide recommendations with comprehensive review and analyses of
the relevant literature for each recommendation, following the guideline development …

Hematopoietic stem cell transplant (HSCT) recipients have a high risk of developing primary
varicella-zoster virus (VZV) infection and reactivation. VZV vaccination may prevent infection …

The incidence of herpes zoster (HZ) in allogeneic hematopoietic stem cell transplantation
(allo-HSCT) recipients is significantly higher than that of the general public. Although routine …

Background Herpesviruses represent common and significant infectious complications after
allogeneic hematopoietic cell transplantation (HCT). In the last decade, major advances in …